• IL-6 nanobody vobarilizumab advances despite equivocal phase II data

    on June 25th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Despite failing its phase II primary endpoint, the single-domain antibody vobarilizumab, being developed for rheumatoid arthritis, will advance to phase III studies. A robust placebo response obscured the strength of clinical response to vobarilizuma[...]
  • Biosimilar immunogenicity studies produce no surprises

    on June 25th, 2017
    MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology[...]
  • Biologics, TNF-inhibitors confer no excess cancer risks upon RA patients

    on June 25th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Biologics and tumor necrosis factor–inhibitors confer very little – if any – risk of malignancy upon those who take them for rheumatoid arthritis, according to a large Swedish registry study. A doubling in the risk of squamous cell carcinoma am[...]
  • Safety data review finds no increased risk of infection from abatacept

    on June 24th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Abatacept doesn’t appear to increase the risk of opportunistic infections among patients with rheumatoid arthritis, Kevin Winthrop, MD, reported at the European Congress of Rheumatology. After reviewing all of the extant safety data on the drug –[...]
  • Apremilast eases PsA symptoms in patients who are naive to biologics

    on June 24th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Aprelimast rapidly improved symptoms for patients with active psoriatic arthritis who were naive to biologics, whether or not they were on background methotrexate. Response to the phosphodiesterase 4-inhibitor also increased with time, Peter Nash, MD[...]
  • Novel ibuprofen formulation cuts GI side effects in patients with knee pain flares

    on June 23rd, 2017
    AT OARSI 2017 LAS VEGAS (FRONTLINE MEDICAL NEWS) – A novel lipid formulation of ibuprofen given at 1,200 mg/day proved noninferior to high-dose standard ibuprofen at 2,400 mg/day for management of episodic knee pain flares in a phase III randomized trial, and it accomplished this with significantl[...]
  • Panel revises spondyloarthritis treat-to-target recommendations

    on June 23rd, 2017
    EXPERT ANALYSIS FROM THE EULAR 2017 CONGRESS MADRID (FRONTLINE MEDICAL NEWS) – The newly revised recommendations from an unaffiliated, international expert panel on a treat-to-target approach for axial spondyloarthritis and psoriatic arthritis has one conspicuous feature that the prior recommendat[...]
  • For opioid-related hospitalizations, men and women are equal

    on June 22nd, 2017
    Equality is not always a good thing, particularly with opioids. In 2005, the rate of opioid-related inpatient hospital stays was 145.6 per 100,000 population for males of all ages and 127.8 for females of all ages. By 2014, however, equality had arrived: Females had a rate of 224.1 per 100,000, comp[...]
  • How to prevent secondary posttraumatic knee osteoarthritis

    on June 21st, 2017
    EXPERT ANALYSIS FROM OARSI 2017 LAS VEGAS (FRONTLINE MEDICAL NEWS) – A variety of evidence-based strategies are available for preventing posttraumatic knee osteoarthritis (KOA) in patients who have already sustained an anterior cruciate ligament (ACL) injury. And they’re generally ignored, accor[...]
  • In Sweden, very few osteoporotic fractures prompt treatment within 12 months

    on June 21st, 2017
    AT THE EULAR 2017 CONGRESS MADRID (FRONTLINE MEDICAL NEWS) – In Sweden, less than 7% of those who experience an osteoporotic fracture receive osteoporosis treatment within the first year, when the risk of a second fracture is the highest. Women are more likely than are men to get a prescription, b[...]
  • Exercise tops NSAIDs for knee osteoarthritis

    on June 20th, 2017
    AT OARSI 2017 LAS VEGAS (FRONTLINE MEDICAL NEWS) – After participating in an 8-week neuromuscular exercise therapy program, patients with mild to moderate knee osteoarthritis showed significantly greater symptomatic improvement at 12 months of follow-up than if they had been instructed to treat wi[...]
  • VIDEO: Childhood second-hand smoke boosts RA incidence

    on June 18th, 2017
    AT THE EULAR 2017 CONGRESS MADRID (FRONTLINE MEDICAL NEWS) – Second-hand smoke exposure to children was about as potent a trigger for future rheumatoid arthritis as active smoking by an adult, based on an analysis of data collected from more than 70,000 French women followed for an average of more[...]
  • Ustekinumab trumps TNF-blockade for enthesitis in patients with psoriatic arthritis

    on June 17th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – The anti-IL-23 antibody ustekinumab cleared enthesitis significantly better than did TNF-blockade in a small, open-label trial of patients with psoriatic arthritis After 6 months on the drug, 71% of those taking the antibody achieved a score of 0 on [...]
Back to top